- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04403165
Locus-coeruleus-funksjon hos normale eldre og AD-risiko (LEAD)
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10029
- Icahn School of Medicine Mount Sinai
-
New York, New York, Forente stater, 10016
- NYU Grossman School of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
- Subjects will be within normal limits on neurological and psychiatric examinations.
- All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
- All subjects will have had a minimum of 12 years of education.
Exclusion Criteria:
- History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
- Significant history of alcoholism or drug abuse.
- Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
- Geriatric Depression Scale (short form)>6.
- Insulin dependent diabetes.
- Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
- Physical impairment of such severity as to adversely affect the validity of psychological testing.
- Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
- History of a first-degree family member with early onset (age <60 years) dementia.
- Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
- Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
- Failure to complete all study visit within 4 months
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Kognitivt normale (CN) eldre voksne
|
Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics. Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio. PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability. Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Tidsramme: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
|
|
Total Rapid Eye Movement (REM) Duration (Min)
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of Time Spent in REM Sleep
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of REM Runs That Are Less Than 5 Minutes
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of Correct Responses on the Picture Test
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Picture Test Response Time
Tidsramme: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Levels of Hyperphosphorylated Tau (P-Tau)
Tidsramme: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Levels will be derived from the plasma and reported in pg/mL |
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Ricardo Osorio, NYU Langone Health
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Psykiske lidelser
- Nevrokognitive lidelser
- Demens
- Tauopatier
- Nevrodegenerative sykdommer
- Alzheimers sykdom
- Undersøkelsesteknikker
- Terapeutikk
- Prøvehåndtering
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Punkteringer
- Kirurgiske prosedyrer, operativ
- Biopsi
- Diagnostiske teknikker, nevrologiske
- Ryggraden
Andre studie-ID-numre
- 20-00002
- 1R21AG067549-01 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All of the individual participant data collected during the trial, after deidentification.
IPD-delingstidsramme
Immediately following publication. No end date.
Tilgangskriterier for IPD-deling
The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .